Search Results
Nov 04, 2025, 09:00 ET Levi & Korsinsky Notifies MoonLake Immunotherapeutics Investors of a Class Action Lawsuit and Upcoming Deadline - MLTX
2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit.
More news about: Levi & Korsinsky, LLP
Nov 03, 2025, 10:04 ET MLTX INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In MLTX To Contact Him Directly To Discuss Their Options
leading national securities law firm, is investigating potential claims against MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) and reminds investors of the December 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been
More news about: Faruqi & Faruqi, LLP
Nov 03, 2025, 09:21 ET MLTX CLASS ACTION NOTICE: Berger Montague Encourages MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Inquire About a Securities Fraud Class Action
Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company") on behalf of investors who purchased MoonLake shares during the period of March 10, 2024 through September 29, 2025
More news about: Berger Montague
Nov 03, 2025, 08:45 ET Lost Money on MoonLake Immunotherapeutics(MLTX)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
Nov. 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX).
More news about: The Gross Law Firm
Oct 31, 2025, 17:20 ET MoonLake Immunotherapeutics Class Action: MLTX Stockholders Should Contact Robbins LLP for Information About the Class Action Against
Company: MoonLake Immunotherapeutics (MLTX) is a Swiss clinical-stage biotechnology company focused on inflammatory diseases driven by interleukin-17 (IL-17), particularly in dermatology and
More news about: Robbins LLP
Oct 31, 2025, 08:45 ET Shareholders that lost money on MoonLake Immunotherapeutics(MLTX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit.
More news about: Levi & Korsinsky, LLP
Oct 30, 2025, 08:48 ET MLTX INVESTOR ALERT: MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman
class action, styled Bridgewood v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08500 (S.D.N.Y), has been filed after MoonLake (NASDAQ: MLTX) announced disastrous Phase 3 trial results for its only product candidate (sonelokimab, or "SLK"), its highly anticipated treatment for patients with
More news about: Hagens Berman Sobol Shapiro LLP
Oct 30, 2025, 08:45 ET The Gross Law Firm Notifies MoonLake Immunotherapeutics Investors of a Class Action Lawsuit and Upcoming Deadline - MLTX
Oct. 30, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX).
More news about: The Gross Law Firm
Oct 28, 2025, 16:50 ET MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.
More news about: THE ROSEN LAW FIRM, P. A.
Oct 28, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in MoonLake Immunotherapeutics of Class Action Lawsuit and Upcoming Deadlines - MLTX
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against MoonLake Immunotherapeutics ("Moonlake" or the "Company") (NASDAQ: MLTX). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Oct 28, 2025, 09:51 ET SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
LLP, a leading national securities law firm, is investigating potential claims against Reuters Research Inc. ("MoonLake" or the "Company") (NASDAQ: MLTX) and reminds investors of the December 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been
More news about: Faruqi & Faruqi, LLP
Oct 28, 2025, 08:45 ET Levi & Korsinsky Notifies Shareholders of MoonLake Immunotherapeutics(MLTX) of a Class Action Lawsuit and an Upcoming Deadline
2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit.
More news about: Levi & Korsinsky, LLP
Oct 27, 2025, 08:45 ET Shareholders that lost money on MoonLake Immunotherapeutics(MLTX) should contact The Gross Law Firm about pending Class Action - MLTX
Oct. 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX).
More news about: The Gross Law Firm
Oct 27, 2025, 08:16 ET MOONLAKE IMMUNOTHERAPEUTICS SECURITIES FRAUD NOTICE: Berger Montague Informs MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors of Securities Fraud Lawsuit
Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company") on behalf of investors who purchased MoonLake shares during the period of March 10, 2024 through September 29, 2025
More news about: Berger Montague
Oct 27, 2025, 07:40 ET MLTX INVESTOR NOTICE: MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
25-cv-08612, and pending in the Southern District of New York – seeks to represent purchasers or acquirers of MoonLake Immunotherapeutics (NASDAQ: MLTX) common stock and charges MoonLake as well as certain of MoonLake's top executives with violations of the Securities Exchange Act of 1934.
More news about: Robbins Geller Rudman & Dowd LLP
Oct 24, 2025, 13:45 ET MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman
class action, styled Bridgewood v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08500 (S.D.N.Y), has been filed after MoonLake (NASDAQ: MLTX) announced disastrous Phase 3 trial results for its only product candidate (sonelokimab, or "SLK"), its highly anticipated treatment for patients with
More news about: Hagens Berman Sobol Shapiro LLP
Oct 24, 2025, 09:00 ET Lost Money on MoonLake Immunotherapeutics(MLTX)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit.
More news about: Levi & Korsinsky, LLP
Oct 23, 2025, 18:00 ET MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.
More news about: THE ROSEN LAW FIRM, P. A.
Oct 23, 2025, 13:41 ET MLTX INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
leading national securities law firm, is investigating potential claims against MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX).
More news about: Faruqi & Faruqi, LLP
Oct 23, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MoonLake Immunotherapeutics - MLTX
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MoonLake Immunotherapeutics ("Moonlake" or the "Company") (NASDAQ: MLTX). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Oct 23, 2025, 05:38 ET MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange
More news about: The Schall Law Firm
Oct 23, 2025, 04:41 ET MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX
MLTX ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of MLTX during the class period listed are
More news about: DJS Law Group LLP
Oct 22, 2025, 18:06 ET Berger Montague PC Investigating Claims on Behalf of MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors After Class Action Filing
Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company") on behalf of investors who purchased MoonLake shares during the period of March 10, 2024 through September 29, 2025
More news about: Berger Montague
Oct 21, 2025, 08:17 ET MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman
MLTX Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO, Oct. 21, 2025 /PRNewswire/ -- A securities class action, styled Bridgewood v. MoonLake
More news about: Hagens Berman Sobol Shapiro LLP
Oct 20, 2025, 09:28 ET MLTX INVESTOR DEADLINE: MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
v. MoonLake Immunotherapeutics, No. 25-cv-08500 (S.D.N.Y.) – seeks to represent purchasers or acquirers of MoonLake Immunotherapeutics (NASDAQ: MLTX) common stock and charges MoonLake as well as certain of MoonLake's executives with violations of the Securities Exchange Act of 1934.
More news about: Robbins Geller Rudman & Dowd LLP